Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit Gains
Placentia, California--(Newsfile Corp. - December 9, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25 sales of $878,937, up 8.3% over FY '24. Net income of $121,980 advanced 14.3% for the same period. CEO and Chairman, W. Richard Ulmer, offered his view of IVRO's progress: "In this past year, Regulatory Agencies around the world announced they have already, or will soon, cease funding for animal testing; some have stopped now. Further, some RA's state OECD validated...
2025-12-09 9:00 AM EST
IVRO's Q3 Packed with Positives; Sales, Profits, and U.S. Government/Global Support for Animal Welfare
Placentia, California--(Newsfile Corp. - August 5, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25, Q3 sales of $234,430, up 39.7% over the same period in FY '24. YTD sales of $675,080 are now 14.4% ahead of FY '24. Net income of $95,556 for three quarters in FY '25 is 17.1% ahead of the same three quarters in FY '24. CEO and Chairman, W. Richard Ulmer, expressed delight with IVRO's noteworthy progress: "In recent months we received quite a...
2025-08-05 9:00 AM EDT
IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances
Placentia, California--(Newsfile Corp. - February 4, 2025) - InVitro International (OTCQB: IVRO) today announced a solid 15.4% sales advance in Q1 of FY '25, totaling $244,143; this compares favorably to Q1 FY '24 sales of $211,625. FY '25 Q1 net income of $33,855 leapt 91.6% over the FY '24 Q1 figure of $17,667. InVitro International's CEO and acting President, W. Richard Ulmer said: "Together with our newly announced M & A activity in Europe, our team is pleased with...
2025-02-04 9:00 AM EST
IVRO Signs MOU to Merge With a European Based Non-Animal Testing Focused Organization
Placentia, California--(Newsfile Corp. - January 14, 2025) - InVitro International (OTCQB: IVRO) previously revealed its strategic intent to accelerate organic growth by pursuing mergers and acquisitions. Today we are excited to announce our initial action to implement this strategy. InVitro International's Board of Directors unanimously approved a Memorandum of Understanding (MOU) to merge with a European based non-animal testing focused organization which has served their market for more...
2025-01-14 9:00 AM EST
InVitro International: Expectations Remain High for Animal Welfare & Growth Opportunities
Placentia, California--(Newsfile Corp. - December 4, 2024) - Today InVitro International (OTCQB: IVRO) announced FY '24 sales of $811,290, up 2.4% vs. FY '23. Net income of $106,704 soared over the prior year's $1,555. Fourth quarter sales of $221,200 were 19.9% ahead of last year's same period while net income of $25,122 fell 48.8%, short of last year's 4th quarter, $49,035.While evaluating FY '24 financial results, CEO W. Richard Ulmer observed: "IVRO's Board of Directors is pleased with...
2024-12-04 9:00 AM EST
InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan
Placentia, California--(Newsfile Corp. - September 3, 2024) - Today InVitro International (OTCQB: IVRO) is pleased to announce that it has engaged Askew Kabala and Company, Inc. as consultant to the company. AKC will act in a business advising, investment banking, management and strategy role to support and advance IVRO's previously announced corporate growth plan. AKC will provide executive and organizational support, including strategy refinement, planning and operational review & more...
2024-09-03 9:00 AM EDT
InVitro International Progresses with Growth Strategies and Continues Profitability
Placentia, California--(Newsfile Corp. - July 31, 2024) - Today, InVitro International (OTCQB: IVRO) announced third quarter FY '24 sales of $167,850, off 16% vs the same quarter last year. Net income of $16,236 compared favorably with losses of $13,162 in the same quarter FY'23. Three quarters FY'24 sales of $590,090 were 3% off FY'23's total of $608,195; however, year to date earnings of $81,582 are 272% ahead of prior year losses of $47,480.IVRO CEO W. Richard Ulmer stated: "Our...
2024-07-31 9:00 AM EDT
InVitro International Reports Positive First Half and Second Quarter FY '24 Results; Also Planning an OTC Markets Uplisting
Placentia, California--(Newsfile Corp. - May 2, 2024) - Today, InVitro International (OTC Pink: IVRO), announced second quarter FY '24 sales of $210,615, up 5.8% compared to $199,090 for the same period FY '23. Net income in the quarter was $47,674 versus losses of $3,356 in '23. First half FY '24 sales advanced 3.4% to $422,240 versus the prior half year's $408,340. First half net income of $65,342 compared favorably (290%) to losses of $34,320 in the first half FY '23....
2024-05-02 9:00 AM EDT
InVitro International Sees Real Positives in Start to FY '24
Placentia, California--(Newsfile Corp. - February 14, 2024) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technologies, announced first Quarter FY '24 sales ending December 31, 2023, of $211,625 up 1.1% vs. the same period in FY '23). Profits of $17,667 were ahead 157% vs. losses of $30,963 in FY' 23, same period. IVRO CEO and President, W. Richard Ulmer, stated: "It remains our intention to grow both...
2024-02-14 9:00 AM EST
InVitro International Announces Fiscal Year End 2023 and Continues Positives
Placentia, California--(Newsfile Corp. - November 13, 2023) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technologies, announced sales for FY '23 ending September 30, 2023 of $792,629 ( -7% vs FY '22); net income was $1,555 (-92% vs FY '22). CEO W. Richard Ulmer commented on the year: "Fiscal Year '23 was another economically challenging one for the majority of global businesses impacted by Covid-...
2023-11-13 9:00 AM EST
IVRO Announces Fiscal Q #3 2023 Results While Continuing M&A Strategy to Make Non-Animal Testing Famous
Placentia, California--(Newsfile Corp. - August 9, 2023) - Today, InVitro International (OTC Pink: IVRO), the 38 year pioneer developer and marketer of animal free testing methods, announced Fiscal 2023 third quarter sales of $199,855, off 16% from prior year's third quarter. However, the net loss of $13,162 was a 58% improvement over last year's $28,938 third quarter loss. FY '23 YTD losses of $47,482 include proposed merger related costs. YTD FY '23 sales of $608,195 are down 10.8% vs. the...
2023-08-09 9:00 AM EDT
IVRO Advances Core Strategy to Make Non-Animal Testing Famous, Announces Fiscal Q2 2023 Results
Placentia, California--(Newsfile Corp. - May 11, 2023) - Today InVitro International (OTC Pink: IVRO), the 38 year pioneer developer and marketer of animal free testing methods, announced Fiscal 2023 second quarter sales of $199,090, off 23% from the same quarter Fiscal 2022; YTD sales are now off 8%. Net loss for this FY '23 quarter of $3,356 was 86% less than last year's loss of $24.6K. Proposed merger related costs have contributed to both Fiscal Year's losses; the YTD now...
2023-05-11 9:00 AM EDT
IVRO Advances Core Strategy to Make Non-Animal Testing Famous, Announces Fiscal Q1 2023 Results
Placentia, California--(Newsfile Corp. - February 8, 2023) - Today InVitro International (OTC Pink: IVRO), the 37 year pioneer developer and marketer of animal free testing methods, announced first fiscal quarter sales of $209,250, an increase of 14% over the same quarter last year. An operating loss of $31,169 was approximately 49% less than the prior years' first fiscal quarter operating loss and partially attributed to initial M&A activity. Our M&A activity has moved forward smoothly and...
2023-02-08 9:00 AM EST
IVRO Continues to Help Make Non-Animal Testing Famous, Releases Fiscal 2022 Results
Placentia, California--(Newsfile Corp. - December 8, 2022) - InVitro International (OTC Pink: IVRO) today announced full year FY2022 sales results of $853,511 (-15%) and net income of $21,276 (-79%).CEO W. Richard Ulmer remarked: "We remain extremely enthusiastic regarding the future of NON-Animal testing despite somewhat disappointing, Covid related, FY '22 financial results. Our October '22 announcement of a Letter of Intent to merge with a well-established, privately owned laboratory adds...
2022-12-08 9:00 AM EST
IVRO Explores Opportunity for Growth
Placentia, California--(Newsfile Corp. - November 16, 2022) - InVitro International (OTC Pink: IVRO) today announced it has signed its first Letter of Intent (LOI) to acquire a privately owned, U.S. based testing laboratory. Over many years this laboratory has served IVRO targeted markets profitably and its principals agree that the future is bright for NON-Animal testing. CEO and Board Chairman, Rich Ulmer, opined, "Following our mission to Make NON-Animal Testing Famous, this initial...
2022-11-16 9:00 AM EST
IVRO Continues to Help Make Non-Animal Testing Famous, Releases Fiscal Q3 2022 Results
Placentia, California--(Newsfile Corp. - August 10, 2022) - InVitro International (OTC Pink: IVRO) today announced year to date Fiscal Year '22, and 3rd quarter financial results. Following a 2nd fiscal quarter sales advance of 27%, 3rd quarter sales slid 23%, leaving year to date sales at -4.9%. Net ordinary income of $11.8K in this fiscal quarter moved YTD net income to $3,349. As previously noted, a GAAP change now requires total net income reported quarterly to include investment gains...
2022-08-10 9:00 AM EDT
IVRO with a Mission to Help Make Non-Animal Testing Famous, Releases Fiscal Q2 2022 Results
Placentia, California--(Newsfile Corp. - April 26, 2022) - InVitro International (OTC PINK: IVRO), an established leader in advancing NON-Animal testing technologies, today announced fiscal 2022 year to date and second fiscal quarter financial results. Second quarter sales of $260,219 were up 27% over the same quarter last year; this increased year to date sales to $443,780, now 9.2% ahead of fiscal 2021 sales for the first half. Second quarter suffered a net loss of $24,636 due in large part...
2022-04-26 9:00 AM EDT
Stock Repurchase by IVRO's Management Shows Increased Confidence in Future of Non-Animal Testing
Placentia, California--(Newsfile Corp. - March 30, 2022) - InVitro International (OTC PINK: IVRO), a 30+ year leader in providing non-animal testing methods, today announced it has completed the re-purchase of 100,000 shares of its common stock. The terms of this transaction were negotiated in December 2021 with a long-term shareholder.IVRO President, Atul Jhalani, said "I believe our decision reflects IVRO management's continuing strong belief in the future of NON-Animal testing; worthy of...
2022-03-30 8:40 AM EDT
IVRO with a Mission to Help Make Non Animal Testing Famous, Releases Fiscal Q1 2022 Results
Placentia, California--(Newsfile Corp. - February 14, 2022) - InVitro International (OTC Pink: IVRO), a leading provider of non-animal testing methods, today announced revenues of $183,561 and net income of $56,940 for its first fiscal quarter of 2022, ending December 31, 2021, compared to revenues and net income of $201,255 and $67,663, respectively, for its first fiscal quarter of 2021. The first fiscal quarter of 2022 earnings benefitted from its second government PPP loan forgiveness much...
2022-02-14 8:13 AM EST
IVRO with a Mission to Help Make Non Animal Testing Famous, Releases Fiscal 2021 Results
Placentia, California--(Newsfile Corp. - December 8, 2021) - InVitro International (OTC Pink: IVRO) announced today that fiscal year 2021 sales for the year ending on September 30th topped $1M for the third consecutive year at $1,003,403. Though off 9% for the year, second half sales were up 47% versus the same period last year. Fiscal 2021 net income of $93,522 (including PPP forgiveness of $106,665) was nearly double the fiscal 2020 net income. In addition, IVRO finished fiscal 2021 with...
2021-12-08 9:00 AM EST